---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-048114"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2024-12-02T23:59:59+00:00"
generated_at: "2026-05-29T11:49:13.065988+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Senti Bio reports 2 of 3 AML patients achieve MRD-negative CR in Phase 1 SENTI-202 trial

## Summary
- Two of three R/R AML patients at lowest dose (1.0B CAR+ NK cells) achieved CR with MRD negativity; both maintain remission (4+ and 3+ months).
- SENTI-202 was generally well-tolerated with no DLTs; adverse events consistent with lymphodepleting chemotherapy and other investigational NK therapies.
- Dose escalation continues at 1.5B cells/dose level; additional safety, efficacy and durability data expected in 2025.
- SENTI-202 transgene detected in peripheral circulation of all patients across cycles, with PK profile similar to other CAR-NK therapies.

## SEC filing metadata
- accession: 0001140361-24-048114
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2024-12-02T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000114036124048114/0001140361-24-048114-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000114036124048114/ef20039399_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-048114
- JSON: https://secwatch.observer/filing/0001140361-24-048114.json
- Plain text: https://secwatch.observer/filing/0001140361-24-048114.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.